Pioneering Hybrid Drugs for Parkinson’s Disease
We are excited to share the latest developments in our work!
Remepy's Hybrid drug for PD is a combination of Levodopa (L-Dopa) and a proprietary treatment protocol of digital interventions
Digital Molecule
Remepy's Digital Molecules are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. Our Digital molecules include digitized, standardized, evidence-based interventions, designed to enhance brain plasticity and connectivity, balance the immune system, and drive behavioral changes. We address disease end-points as well as side-effects and disease comorbidities.
Sign up to learn moreRemepy’s Hybrid Drug for
Parkinson’s Disease
Combined with L-Dopa, Remepy’s Hybrid Drug for PD provides digital interventions that address fine and gross motor skills, speech therapy, cognition, sleep, stress reduction, attention training, and psychoeducation. The patient experience includes a multidisciplinary care team guiding the patient through the daily activities and reminders to take the medication. The digital protocol is personalized and adapts to each patient progress and needs.
Learn more about Hybrid Drugs and about Remepy’s Hybrid Drug for Parkinson’s Disease
Learn more about Hybrid Drugs and about Remepy’s Hybrid Drug for Parkinson’s Disease
Join our innovative community!
We are looking to learn from you and to work together to improve care for Parkinson’s Disease patients.
If you are interested in learning more, sign up below.
If you are interested in learning more, sign up below.
Managing Disease at the Intersection of Biology, Behavior & Therapy
